2020
DOI: 10.1002/med.21755
|View full text |Cite
|
Sign up to set email alerts
|

Analogies and differences between cirrhotic cardiomyopathy and hepatopulmonary syndrome

Abstract: Cirrhotic cardiomyopathy and hepatopulmonary syndrome are two quite frequent clinical entities that may complicate the course of liver cirrhosis. The common pathophysiological origin and the same clinical presentation make them difficult to compare. Cirrhotic cardiomyopathy and hepatopulmonary syndrome may start with dyspnea and breathlessness but the former is characterized by a chronic cardiac dysfunction and the latter by a defect of oxygenation due to pulmonary shunts formation. The focus is to differentia… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
4
0

Year Published

2021
2021
2025
2025

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(4 citation statements)
references
References 73 publications
0
4
0
Order By: Relevance
“…However, in the diagnosis of the diastolic dysfunction of the myocardium, doppler techniques are used [4,35]. Echocardiography with saline contrast helps diagnose the hepatopulmonary syndrome and portopulmonary hypertension in the case of patients with end stage liver disease (ESLD) with portal hypertension [58].…”
Section: Echocardiographymentioning
confidence: 99%
“…However, in the diagnosis of the diastolic dysfunction of the myocardium, doppler techniques are used [4,35]. Echocardiography with saline contrast helps diagnose the hepatopulmonary syndrome and portopulmonary hypertension in the case of patients with end stage liver disease (ESLD) with portal hypertension [58].…”
Section: Echocardiographymentioning
confidence: 99%
“… 4 IPVD seems to have a limited impact on survival or other outcomes of patients with CLD. 1 , 5 As the only curable treatment for HPS is liver transplantation, 6 preventing CLD patients from developing HPS is of great importance. However, only 0.45% of CLD patients are diagnosed with HPS, and the diagnostic accuracy is only 22.5%, 7 highlighting the need for specific markers in this field.…”
Section: Introductionmentioning
confidence: 99%
“… 10 , 14 In contrast to the high success rate of the HPS experimental model, the incidence of HPS in CLD patients is relatively low. 6 This may partially explain why some markers or targets that are effective in experimental models are not appropriate for HPS patients. 14 Second, the levels of VEGF family members and their receptors in patients with CLD are usually elevated, 15 , 16 but only some patients will develop HPS.…”
Section: Introductionmentioning
confidence: 99%
“…Additionally, the proportions of circulating vasoactive intestinal peptide, glucagon, tumour necrosis factor (TNF), prostacyclin, nitric oxide, endothelin-1, and endothelin-3, are not down-regulated by the liver and are raised. 2 Owing to these haemodynamic characteristics, patients with compensated or decompensated liver cirrhosis potentially suffer from various repercussions involving deficient cardiac health which usually is not discerned. 3 Besides, insufficient heart function could contribute to more hepatic damage.…”
Section: Introductionmentioning
confidence: 99%

Do you have to evaluate the heart of the cirrhotic patients?

Mohammed Hussien Ahmed,
Mohammed Said Radwan,
Ibrahim Fathi Amer
et al. 2023
J Pak Med Assoc